PPARa activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats by Rodríguez Vilarrupla, Aina et al.
Research ArticlePPARa activation improves endothelial dysfunction and
reduces fibrosis and portal pressure in cirrhotic rats
Aina Rodríguez-Vilarrupla1,⇑, Bàrbara Laviña1, Héctor García-Calderó1, Lucia Russo1,
Eugenio Rosado1, Núria Roglans2, Jaume Bosch1, Joan Carles García-Pagán1
1Hepatic Hemodynamic Laboratory, Liver Unit, IMDIM, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and
Ciberehd, University of Barcelona, Spain; 2Pharmacology Unit, Department of Pharmacology and Therapeutic Chemistry,
School of Pharmacy, University of Barcelona, SpainBackground & Aims: Peroxisome proliferator-activated receptor  2012 European Association for the Study of the Liver. Published
a (PPARa) is a transcription factor activated by ligands that reg-
ulates genes related to vascular tone, oxidative stress, and fibro-
genesis, pathways implicated in the development of cirrhosis and
portal hypertension. This study aims at evaluating the effects of
PPARa activation with fenofibrate on hepatic and systemic hemo-
dynamics, hepatic endothelial dysfunction, and hepatic fibrosis in
CCl4-cirrhotic rats.
Methods: Mean arterial pressure (MAP), portal pressure (PP), and
portal blood flow (PBF) were measured in cirrhotic rats treated
with oral fenofibrate (25 mg/kg/day, n = 10) or its vehicle
(n = 12) for 7 days. The liver was then perfused and dose-relaxa-
tion curves to acetylcholine (Ach) were performed. We also eval-
uated Sirius Red staining of liver sections, collagen-I mRNA
expression, and smooth muscle actin (a-SMA) protein expression,
cyclo-oxygenase-1 (COX-1) protein expression, and cGMP levels
in liver homogenates, and TXB2 production in perfusates. Nitric
oxide (NO) bioavailability and eNOS activation were measured
in hepatic endothelial cells (HEC) isolated from cirrhotic rat
livers.
Results: CCl4 cirrhotic rats treated with fenofibrate had a signifi-
cantly lower PP (29%) and higher MAP than those treated with
vehicle. These effects were associated with a significant reduction
in hepatic fibrosis and improved vasodilatory response to acetyl-
choline. Moreover, a reduction in COX-1 expression and TXB2
production in rats receiving fenofibrate and a significant increase
in NO bioavailability in HEC with fenofibrate were observed.
Conclusions: PPARa activation markedly reduced PP and liver
fibrosis and improved hepatic endothelial dysfunction in cirrhotic
rats, suggesting it may represent a new therapeutic strategy for
portal hypertension in cirrhosis.Journal of Hepatology 20
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Increased resistance to portal blood flow is the primary factor in
the pathophysiology of portal hypertension, the main complica-
tion of cirrhosis [1]. Increased resistance to portal blood flow in
cirrhotic livers results both from architectural alterations of the
liver parenchyma and from a dynamic increase in the hepatic
vascular tone. Sinusoidal endothelial cell dysfunction, character-
ized by impaired endothelium-dependent vasodilation, is an
important mechanism of the increased vascular tone of cirrhotic
livers and has been attributed, among others, to increased release
of cyclo-oxygenase-1 (COX-1)-derived vasoconstrictive prosta-
noids [2,3] and to reduced bioavailability of the vasodilator nitric
oxide (NO) within the liver [4].
Peroxisome proliferator-activated receptor a (PPARa) is a
member of the nuclear receptor superfamily and acts as a
ligand-activated transcription factor. PPARa is predominantly
expressed in the liver [5]. Identification of PPAR target genes first
illustrated that PPARa is a major regulator of fatty acid homeo-
stasis [6], but it is well recognized that the transcriptional pro-
gram of PPARa also includes genes involved in the regulation of
vascular tone, oxidative stress, and fibrosis [7,8].
PPARa receptors are activated by natural or synthetic ligands,
such as fibrates [9]. Fibrates are first-line drugs in the treatment
of hyperlipidemia and have also been shown to improve endothe-
lial dysfunction in arterial hypertension [10], diabetes [11], and
ischemia/reperfusion injury [12]. PPARa is expressed in endothe-
lial cells and it has been demonstrated that PPARa activation is
involved in several endothelial functions as leukocyte recruit-
ment, inflammatory signalling, and vascular functions [13]. The
beneficial effects of fenofibrate on vascular function may be
partly due to improved endothelial NO availability, as it has been
demonstrated that PPARa activation increases NO production in
endothelial cells [14–16]. Besides, PPARa activation has also been
shown to decrease the expression of COX-1 and the release of
thromboxane A2 (TXA2) [17]. Additionally, it has been observed
that PPARa activation exerts antifibrotic effects on the TAA-
induced model of hepatic fibrosis [18]. Altogether these findings12 vol. 56 j 1033–1039
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suggest that activation of PPARa receptors could have beneficial
effects in the pathophysiological mechanisms involved in the
development of portal hypertension in cirrhosis.
The aim of this study was to evaluate the effects of PPARa
activation with fenofibrate on hepatic and systemic hemodynam-
ics, hepatic endothelial dysfunction, and hepatic fibrosis in CCl4-
cirrhotic rats.Materials and methods
Experimental protocols
Cirrhosis was induced in male Wistar rats (50–75 g) by inhalation of CCl4 three
times a week during approximately 12–15 weeks as previously described [19].
When cirrhotic rats had developed ascites, administration of CCl4 and phenobarbi-
tal was discontinued. One week later, the animals were distributed randomly into
two groups. Each group was fed, respectively, with a control diet or with a diet con-
taining fenofibrate (Sigma, Tres Cantos, Madrid, Spain) to proportionate a daily
therapeutic dose of 25 mg/kg for 7 days (which is in the range previously reported
in rats with no toxic effects) [20]. The diets were prepared as previously described
[21] by soaking in an acetone solution of the drug. To avoid any possible effect of
the solvent, the control diet was also soaked in acetone and dried. The animals
were kept in environmentally controlled animal facilities at the Institut d’Investi-
gacions Biomèdiques August Pi i Sunyer (IDIBAPS). All experiments were approved
by the Laboratory Animal Care and Use Committee of the University of Barcelona
and were conducted in accordance with Guide for the Care and Use of Laboratory
Animals (National Institutes of Health, NIH Publication 86–23, revised 1996).
Evaluation of PPARa activation
PPARa gene expression
Expression of PPARa was analyzed in total RNA from cirrhotic livers using prede-
signed gene expression assays obtained from Applied Biosystems (Applied Bio-
systems, Foster City, CA) according to the manufacturer’s protocol and reported
relative to the endogenous control 18S. All PCR reactions were performed in
duplicate and using nuclease–free water as no template control.
Protein expression of PPARa and Acyl-Coenzyme A oxydase 1
PPARa protein expression was determined in hepatic crude nuclear extracts
obtained as previously described [22], using a mouse antibody against PPARa
(Abcam, Cambridge, UK) and the expression of Acyl-Coenzyme A oxydase 1
(ACOX1), a target gene of PPARa, was determined in hepatic samples obtained
as previously described [23], using a mouse antibody against ACOX1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Both antibodies were incubated overnight at
4 C followed by incubation with rabbit anti-mouse HRP-conjugated secondary
antibody (1:10,000, 1 h, room temperature; Stressgen, Victoria, BC, Canada). Blots
were revealed by chemiluminiscence. Protein expression was determined by den-
sitometric analysis using the Science Lab, Image Gauge (Fuji Photo Film GMBH,
Düsseldorf). Quantitative densitometric values were normalized to TATA-binding
protein (TBP; Abcam) for PPARa or to GAPDH (Sta Cruz) for ACOX.
Electrophoretic mobility shift assays (EMSA)
Electrophoretic mobility shift assay (EMSA) to evaluate PPARa binding activity
was performed as described previously [24]. The DNA sequence of the double-
stranded oligonucleotide used was: consensus binding site of PPAR response ele-
ment, 50-CAAAACTAGGTCAAAGGTCA-30 (Santa Cruz Biotec.). Oligonucleotides
were labeled and then, to separate the labeled probe from the unbound ATP,
the reaction mixture was eluted in a Nick column (Amersham Biosciences) fol-
lowing the manufacturer’s instructions. Eight micrograms of crude nuclear pro-
teins was incubated for 10 min on ice in binding buffer (10 mM Tris–HCl pH
8.0, 25 mM KCl, 0.5 mM DTT, 0.1 mM EDTA pH 8.0, 5% glycerol, 5 mg/ml BSA,
and 50 lg/ml poly(dI-dC)), in a final volume of 15 ll. The labeled probe (approx-
imately 55,000 cpm) was added and the reaction was incubated for 20 min at
room temperature. Moreover, for supershift assays, antibodies were added before
incubation with the labeled probe for a further 30 min at 4 C. The involvement of
PPARa in the formation of specific bands is shown by the appearance of three
marked supershifted bands when hepatic nuclear extracts were co-incubated
with PPARa antibody, whereas Oct-1 antibody was used to demonstrate that
supershifts were not due to an unspecific interference produced by the presence1034 Journal of Hepatology 2012in the incubation medium of immunoglobulin proteins. Protein–DNA complexes
were resolved by electrophoresis at 4 C on a 5% acrylamide gel and subjected to
autoradiography. PPARa and octamer motif-1 transcription factor (Oct-1) anti-
bodies were from Santa Cruz Biotec.
In vivo hemodynamic studies
Rats were anesthetised with ketamine hydrochloride (100 mg/kg; Merial Labora-
tories, Barcelona, Spain) plus midazolam (5 mg/kg; Laboratorios Reig Jofré, Barce-
lona, Spain) intraperitoneally. PE-50 catheters were introduced into the femoral
artery to measure mean arterial pressure (MAP; mmHg) and into the ileocolic
vein to measure portal pressure (PP, mmHg). Perivascular ultrasonic flow probes
connected to a flowmeter (Transonic Systems Inc., Ithaca, NY, USA) were placed
around the portal vein, as close as possible to the liver to avoid portal-collateral
blood flow, to measure portal blood flow (PBF; mlmin1) perfusing the liver.
Blood pressures and flows were registered on a multichannel computer-based
recorder (PowerLab; AD Instruments, Colorado Springs, CO). The temperature of
the animals was maintained at 37 ± 0.5 C and hemodynamic data were collected
after a 20-min stabilization period.
Biochemical measurements
At the end of data collection, blood samples from a peripheral vein were taken for
biochemical analysis. Serum was separated within 15 min and frozen at 70 C
for subsequent analysis. Cholesterol, AST, ALT, albumin, and triglycerides (TG)
levels were determined by current standard protocols.
Evaluation of endothelial function
After in vivo hemodynamic measurements, livers were quickly isolated and per-
fused by a flow-controlled perfusion system as previously described [25]. The
perfused rat liver preparation was allowed to stabilize for 20 min before vasoac-
tive substances were added. The intrahepatic microcirculation was preconstricted
by adding the a1-adrenergic agonist methoxamine (Mtx; 104 mol/L; Sigma) to
the reservoir. After 5 min, concentration–response curves to cumulative doses
of acetylcholine (Ach; 107, 106, and 105 mol/L; Sigma) were evaluated.
Responses to Ach were calculated as per cent change in portal perfusion pressure
[3]. The gross appearance of the liver, stable perfusion pressure, bile production
over 0.4 ll/min/g of liver and a stable buffer pH (7.4 ± 0.1) were monitored during
this period. If any viability criteria were not satisfied, the experiment was
discarded.
Evaluation of NO bioavailability
Isolation and culture of hepatic endothelial cells (HEC)
HEC were isolated from control and cirrhotic rats as previously described [26,27].
Briefly, after collagenase perfusion of the livers and isopycnic sedimentation of
the resulting dispersed cells through a two-step density gradient of Percoll, pure
monolayer cultures of HEC were established by selective attachment on a sub-
strate of rat tail collagen type I. Afterwards, cells were cultured in Roswell Park
Memorial Institute (RPMI)-1640 medium and studies were performed on cells
from the first passage, 12 h after their isolation, to preserve their typical pheno-
type [28].
PPARa activation in HEC
To determine whether PPARa activation could increase NO bioavailability in HEC
isolated from cirrhotic rat livers (CH-HEC), CH-HEC were incubated for 30 min at
37 C with vehicle (DMSO) or with fenofibrate (100 lM). Then, we evaluated NO
levels by DAF-FM-DA staining and eNOS activation by Western blot in different
subsets of CH-HEC.
Measurement of NO levels in HEC
In situ NO levels in CH-HEC were assessed using 4-amino-5-methylamino-20 ,70-
difluorofluorescein diacetate (DAF-FM-DA) (Molecular Probes, Inc., Eugene, OR)
on a laser scanning confocal microscope (model TCS-SL DMIRE2, Leica, Wetzlar,
Germany) as described [26]. Quantitative analysis was obtained by averaging
the peak relative fluorescent intensity (optical density arbitrary units) of each cell
using Image J 1.43 m software (NIH, USA) and normalization of the fluorescent
result by the total number of cultured cells counted from each corresponding dig-
italized phase contrast microscope image.vol. 56 j 1033–1039
Table 1. Effects of fenofibrate treatment on metabolic parameters.
Parameter CH vehicle
n = 10 n = 10
p
Body weight (g) 341 ± 41 379 ± 83 0.12
Serum cholesterol (mg/dl) 89 ± 7 65 ± 7 0.03
Serum triglycerides (mg/dl) 43 ± 16 34 ± 17 0.2
ALT (IU/L) 99 ± 7 101 ± 17 0.92
AST (IU/L) 240 ± 28 225 ± 43 0.77
Albumin (g/L) 29 ± 3 28 ± 3 0.81
CH fenofibrate
Data are means ± SD. CH vehicle denotes cirrhotic rats receiving vehicle, and CH
fenofibrate denotes cirrhotic rats receiving fenofibrate.
JOURNAL OF HEPATOLOGYeNOS activation in HEC
eNOS activation was determined by eNOS phosphorylation/eNOS total ratio by
Western blot in CH-HEC treated with fenofibrate (n = 6) or vehicle (n = 6) as pre-
viously described [29].cGMP levels
Measurements of cGMP, a marker of NO bioavailability, were performed in rat
liver homogenates from cirrhotic rats treated with fenofibrate (n = 8) or vehicle
(n = 8) by enzyme immunoassay as previously described [19,25].Evaluation of COX pathway
Protein expression of COX-1
COX-1 expression was determined in hepatic samples using a mouse antibody
against COX-1 (Cayman Chem Co., Tallin, Estonia).
Measurement of thromboxane B2
In liver-perfusion experiments, samples of the perfusate were obtained before
Mtx administration and after the dose–response to Ach. The samples were
stored at 80 C and thromboxane B2 (TXB2), the end metabolite of TXA2,
was quantified in duplicate using a commercially available enzyme immunoas-
say (Cayman Chem Co.) [30]. TXB2 production was expressed as absolute incre-
ment over baseline before Mtx administration and after dose–response curve
to Ach.
Evaluation of hepatic fibrosis
Quantification of hepatic fibrosis
Livers from cirrhotic rats were fixed in 10% formalin, embedded in paraffin, sec-
tioned and stained with 0.1% Sirius Red, photographed, and analyzed using a
microscope equipped with a digital camera. Six fields from each slide were ran-
domly selected, and the red-stained area per total area was measured using Axi-
oVision software [31]. Values are expressed as the mean of 30–42 fields taken
from 5 to 7 animals per group.
Collagen I and MMPs/TIMPs gene expression
Hepatic mRNA expression of collagen I, MMP2, MMP9, MMP13, TIMP1, and TIMP2
was analyzed using predesigned gene expression assays obtained from Applied
Biosystems as described above.
Protein expression of aSMA
Hepatic protein expression of a-smooth muscle actin (aSMA) was determined by
Western blot in hepatic samples using a mouse antibody against aSMA (Sigma).
Statistical analysis
Statistical analysis was performed using SPSS 16.0 for Windows statistical pack-
age (SPSS Inc., Chicago, IL). All results are expressed as mean ± SD in the text
whereas in figures are represented by boxplots with median and interquartile
range. Comparisons between groups were performed with the Student’s t-test
or Mann–Whitney t-test for unpaired data when adequate. Differences were con-
sidered significant at a p value <0.05.Journal of Hepatology 2012Results
All rats had macroscopic cirrhosis and signs of portal hyperten-
sion. Weight gain during the study was similar between fenofi-
brate-treated and vehicle-treated rats. No rat died during
treatment. There were no significant differences in AST, ALT,
and albumin levels between the two groups of cirrhotic rats
(Table 1). Rats treated with fenofibrate had significanly lower
serum cholesterol levels. Serum triglyceride levels were also
lower, although they did not reach statistical significance proba-
bly because of the small sample size (Table 1).
Fenofibrate treatment activates PPARa in CCl4-cirrhotic rats
CCl4-cirrhotic rats treated with fenofibrate had an increase in
PPARa mRNA expression (Fig. 1A) and in PPARa protein expres-
sion (Fig 1A). Fig. 1B shows the pattern of retardation bands
obtained in EMSA, performed by incubating a PPRE oligonucleo-
tide probe and hepatic nuclear extracts obtained from vehicle-
and fenofibrate-treated cirrhotic rats. An enhanced PPARa bind-
ing activity was demonstrated when comparing the intensity of
the shifted bands (IC) between samples from vehicle- and fenof-
ibrate-treated cirrhotic rats. Fenofibrate treatment produced a
marked significant increase in the intensity of bands II and III
(Fig. 1C). Increased PPARa activity was associated with an aug-
mented protein expression of one of its target genes, ACOX1
(Fig. 1D).
PPARa activation lowers portal pressure in CCl4-cirrhotic rats
Portal pressure (PP) was significantly lower in cirrhotic rats trea-
ted with fenofibrate than in those treated with vehicle (mean
decrease 29%) (Table 2), without significant changes in PBF. In
addition, MAP was significantly higher in cirrhotic rats treated
with fenofibrate than in rats treated with vehicle (Table 2).
PPARa activation improves endothelial dysfunction in CCl4-cirrhotic
rats
Baseline portal perfusion pressure was significantly lower in liv-
ers from cirrhotic rats treated with fenofibrate than in those trea-
ted with vehicle (7.4 ± 1.2 mm Hg vs. 10.3 ± 1.9 mm Hg; p <0.05).
As expected, livers from cirrhotic rats treated with vehicle
exhibited an impaired vasodilatory response to Ach. Fenofibrate
treatment significantly improved vasorelaxation in response to
Ach (Fig. 2A).
PPARa activation increases NO bioavailability in HEC
We assessed NO bioavailability by DAF-FM-DA staining in HEC
isolated from cirrhotic rat livers (CH-HEC). Fenofibrate adminis-
tration promoted a significant increase in NO in CH-HEC
(Fig. 2B). This was associated with a trend to increase eNOS phos-
pho/total ratio in CH-HEC (1 ± 0.49 vs. 2.49 ± 2.34; p = 0.1) and
cGMP levels in the whole liver (19.6 ± 6.7 vs. 24.3 ± 5.1; p = 0.16).
PPARa activation attenuates COX-1 activation in CCl4-cirrhotic rats
COX-1 protein expression was significantly reduced in cirrhotic
livers treated with fenofibrate as compared with those treated





























































































































Band I Band II Band III
Fig. 1. Effects of fenofibrate treatment on PPARa activation. (A) Left panel:
relative PPARa mRNA levels in hepatic samples from CCl4-cirrhotic rats treated
with vehicle (n = 11; Veh) or fenofibrate (n = 10; FF) normalized to an
endogenous reference gene (18S). Values (median ± interquartile range) are
normalized to Veh-treated liver expression. Right panel: representative
Western blot image of PPARa in nuclear extracts from CCl4-cirrhotic rat livers
treated with vehicle (Veh; n = 6) or fenofibrate (FF; n = 6). Densitometric
analysis in arbitrary units, normalized to TATA-binding protein (TBP), showed
an increased expression of PPARa in fenofibrate-treated CCl4-cirrhotic rat livers.
(B) The left side of the figure consists of a representative EMSA autoradiog-
raphy, showing the pattern of retardation bands obtained by incubating hepatic
nuclear extracts from CCl4-cirrhotic rats treated with vehicle (n = 4; Veh) or
fenofibrate (n = 6; FF) with a PPRE oligonucleotide, forming at least three
specific bands (bands I–III). In the right part of the figure, the involvement of
PPARa in the formation of specific bands is shown by the appearance of
marked supershifted (IC) bands when hepatic nuclear extracts were co-
incubated with PPARa antibody (Ab). Oct-1 Ab was used to demonstrate that
supershifts were not due to an unspecific interference produced by the
presence in the incubation medium of immunoglobulin proteins. (C) Box plot
Table 2. Effects of fenofibrate treatment on systemic and hepatic
hemodynamics.
Parameter CH vehicle CH fenofibrate
n = 10 n = 8
p
PP (mmHg) 17.1 ± 2.5 12.2 ± 1.7 0.001
PBF (ml/min) 14.6 ± 1.8 11.6 ± 1.4 0.21
MAP (mmHg) 83 ± 15 103 ± 20 0.02
HR (bpm) 320 ± 36 354 ± 48 0.48
Data are means ± SD. MAP, mean arterial pressure; PP, portal pressure; PBF, portal
blood flow; HR, heart rate. CH vehicle denotes cirrhotic rats receiving vehicle, and
CH fenofibrate denotes cirrhotic rats receiving fenofibrate.
























































Fig. 2. Effect of PPARa activation on endothelial function of CCl4 cirrhotic
rats. (A) Endothelium-dependent vasorelaxation to acetylcholine (Ach) in isolated
and perfused livers of CCl4-cirrhotic rats treated with vehicle (Veh; n = 7) or
fenofibrate (FF; n = 7). Results are expressed as mean ± SEM. Fenofibrate treat-
ment significantly improved the impaired vasodilatory response to Ach in CCl4-
cirrhotic rat livers. PP, portal perfusion pressure. (B) Effects of PPARa activation
on NO bioavailability in hepatic endothelial cells. Left panel, fluorescent detection
of intracellular nitric oxide (NO) in hepatic endothelial cells (HEC) isolated from
cirrhotic rat livers (CH-HEC). Representative images (confocal microscopy) of
DAF-FM-DA fluorescence from CH-SEC treated with vehicle (Veh) or fenofibrate
(FF). Original magnification, 40; bar 10 lm. Right panel, the fluorescence
intensity of DAF-FM-DA in arbitrary units was normalized to the total number of
cells. The data shown are from 4873 individual Veh- and 4196 fenofibrate-CH-SEC
obtained from three different experiments. Fenofibrate administration promoted
a significant increase in NO bioavailability; ⁄p <0.01 vs. Veh-treated CH-SEC.
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1036 Journal of Hepatology 2012ished in the perfusate of cirrhotic livers treated with fenofibrate
in comparison to those treated with vehicle (Fig. 3B).
PPARa activation attenuates intrahepatic fibrosis in CCl4-cirrhotic
rats
As expected, cirrhotic rats exhibited a marked architectural dis-
tortion with abundant fibrosis revealed by extensive collagenanalysis of the relative intensity of the specific PPARa bands I, II, and III. (D)
Representative Western blot image of ACOX1 in CCl4-cirrhotic rat livers treated
with vehicle (Veh; n = 6) or fenofibrate (FF; n = 8) and densitometric analysis in
arbitrary units, normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), showed an increased expression of ACOX in fenofibrate-treated
CCl4-cirrhotic rat livers.
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Fig. 3. Effects of PPARa activation on COX-1 activation in CCl4-cirrhotic rats.
(A) Representative Western blot image of COX-1 in CCl4-cirrhotic rat livers
treated with vehicle (Veh; n = 6) or fenofibrate (FF; n = 8) and densitometric
analysis in arbitrary units, normalized to glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), showed a decreased expression of COX-1 in fenofibrate-treated
CCl4-cirrhotic rat livers. (B) TXB2 production in Veh- or fenofibrate-treated CCl4-
cirrhotic rat livers. Values represent median ± interquartile range; ⁄p <0.01 vs.
vehicle-treated CCl4-cirrhotic rats.
JOURNAL OF HEPATOLOGYstaining. Importantly, rats receiving fenofibrate had a 50% reduc-
tion in collagen deposition resulting in thinner septa and larger
regenerating nodules than vehicle-treated cirrhotic animals
(Fig. 4A). This was associated with a significant decrease in type
I collagen mRNA levels (Fig. 4B) and with a marked decrease in
aSMA expression, a surrogate marker of hepatic stellate cell acti-
























































































































Fig. 4. Effects of PPARa activation on hepatic fibrosis in CCl4-cirrhotic rats. (A) Left
fenofibrate (FF)- or vehicle (Veh)- treated CCl4-cirrhotic rats (original magnification 50)
in fenofibrate- or Veh-treated CCl4-cirrhotic rats, ⁄⁄p <0.01. (B) Collagen I mRNA expressio
normalized to an endogenous reference gene (GAPDH). Values (median ± interquartile ra
blot analysis of aSMA in livers from Veh (n = 6) or fenofibrate-treated (n = 8) CH rats and d
a decrease of aSMA expression in fenofibrate-treated CCl4-cirrhotic rats; ⁄p <0.05 vs. vehi
expression levels in CCl4-cirrhotic rat livers treated with Veh (n = 11) or fenofib
(median ± interquartile range) are normalized to Veh-treated livers expression; ⁄p <0.05
Journal of Hepatology 2012decreased MMP2, MMP9, MMP13, TIMP1, and TIMP2 mRNA levels
(Fig. 4D).Discussion
Increased resistance to portal blood flow is the primary factor
leading to portal hypertension in cirrhosis [1]. Much of this
increase is determined by structural changes in the liver and is
further aggravated by an increase in hepatic vascular tone. In a
healthy liver, the endothelium is able to release vasoactive sub-
stances to properly modulate intrahepatic hemodynamics. By
contrast, the hepatic vascular bed of cirrhotic livers exhibits
endothelial dysfunction, which represents the first sign of micro-
vascular injury at the organ level [32].
Substantial data suggest that PPARa regulates processes that
are involved in the regulation of vascular function [33]. Impor-
tantly, PPARa is expressed in the liver and in vascular endothelial
cells [34], suggesting that PPARa activation may exert beneficial
effects on the vascular wall [35] also in the liver. Fibrates activate
PPARa, which results in a wide spectrum of downstream effects,
including regulation of target genes related to the pathophysio-
logical mechanisms involved in the development of portal hyper-
tension in cirrhosis, such as vascular tone, oxidative stress, and
fibrosis.
Our study clearly shows that fenofibrate treatment reduces
fibrosis, improves hepatic endothelial dysfunction and reduces















































































































panel, representative histological images of livers stained with Sirius Red from
. Right panel, quantification of liver fibrosis (Sirius Red staining area per total area)
n levels in CCl4-cirrhotic rat livers treated with Veh (n = 11) or fenofibrate (n = 10)
nge) are normalized to Veh-treated livers expression. (C) Representative Western
ensitometric quantification in arbitrary units (AU), normalized to GAPDH, showed
cle-treated CCl4-cirrhotic rats. (D) MMP2, MMP9, MMP13, TIMP1, and TIMP2 mRNA
rate (n = 10) normalized to an endogenous reference gene (GAPDH). Values
, ⁄⁄p <0.01.
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rats receiving fenofibrate than in those receiving vehicle. It is
worth remembering that this reduction is well above the 20% tar-
get reduction that has been associated with an improvement in
prognosis in patients with cirrhosis [36].
Our results suggest that reduction in PP is mainly due to the
effect of fenofibrate improving the architectural abnormalities
of the cirrhotic liver. Histopathological analysis revealed that
fenofibrate markedly atttenuates intrahepatic fibrosis. Specifi-
cally, we observed a robust attenuation of septal thickness and
an increase in nodule size. It is important to emphasize that
wider septal thickness and lower nodule size have been shown
to be associated with a more severe degree of portal hypertension
[37]. Further reinforcing the concept that fenofibrate reduced
fibrosis was the observed significant reduction in collagen I mRNA
expression and a-SMA protein expression (a surrogate of HSC
activation). These findings are in agreement with previous stud-
ies showing that PPARa activation is implicated in the regulation
of fibrosis in other experimental models [38]. In fact, PPARa acti-
vation prevents fibrosis in a TAA-induced hepatic fibrosis model
[18].
Fenofibrate also improves intrahepatic endothelial dysfunc-
tion. We have previously shown that endothelial dysfunction in
cirrhotic livers is due, at least in part, to an increased production
of COX-1-derived prostanoids [3]. Interestingly, a previous study
reported that fenofibrate has a protective effect in an experimen-
tal model of age-associated endothelial dysfunction, by reducing
the expression of COX-1 and the release of TXA2 [17]. Our study
suggests that this also happens in CCl4-cirrhotic rats, where
fenofibrate treatment was associated with a reduction of COX-1
protein expression and TXA2 production. To what extent this
effect on the COX signalling pathway represents a direct effect
of fenofibrate or it is due to improvement of the hepatic architec-
ture remains conjectural but it is likely that both mechanisms are
involved.
A second factor involved in hepatic endothelial dysfunction in
cirrhosis is a reduced intrahepatic NO availability. Fenofibrate
incubation promoted a significant increase in NO bioavailability
in endothelial cells isolated from cirrhotic livers that was associ-
ated with a trend for an increase in eNOS activation in endothelial
cells and cGMP levels in the whole tissue.
Another important finding of the present study is the effect of
fenofibrate increasing arterial pressure in cirrhotic rats. It is rea-
sonable to hypothesize that improved hepatic hemodynamics in
cirrhosis may have beneficial effects on the splanchnic and sys-
temic circulation, by deactivating factors triggered by the
increased intrahepatic resistance. In that regard, we and others
have previously observed a similar improvement in systemic
hypotension in studies where NO availability has been improved
by tetrahydrobiopterin supplementation [39] or by transducing
actived-Akt into the liver of CCl4-cirrhotic rats [40]. In any case,
the increase in arterial pressure represents an additional benefit
of fenofibrate treatment.
Fenofibrate has been extensively used in the treatment of
dyslipidemia, since it markedly decreases cholesterol levels and
has an excellent safety profile [41]. In addition, pilot studies in
patients with primary biliary cirrhosis and non-alcoholic fatty
liver disease suggest that this drug is safe in patients with liver
diseases, in whom it may improve liver function [42,43].
In conclusion, our data provides evidence that PPARa activa-
tion may have beneficial effects in several mechanisms involved
in the pathophysiology of portal hypertension, leading to a1038 Journal of Hepatology 2012regression of liver fibrosis in cirrhotic rats, to a correction of
endothelial dysfunction, to a reduction of portal pressure and to
an amelioration of systemic hypotension. This new therapeutic
strategy for portal hypertension should obviously be confirmed
in patients with cirrhosis.Conflict of interest
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